Non-small cell lung cancer · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Carboplatin, Pemetrexed, Pembrolizumab Variant #01 | ERBB2 | R 83 725 | 21d | ~11.2 mo | — | ~17 | ~R 1 423 331 PFS proxy · indirect | 1 |
Cisplatin, Pemetrexed, Pembrolizumab Variant #01 | ERBB2 | R 83 075 | 21d | ~11.2 mo | — | ~17 | ~R 1 412 272 PFS proxy · indirect | 1 |
Trastuzumab deruxtecan monotherapy Variant #01 | ERBB2 | R 81 019 | 21d | ~15.5 mo | ~22.9 mo | ~23 | ~R 1 863 446 PFS proxy · indirect | 11 |
Capmatinib monotherapy Variant #01 Partial | MET | — | 28d | — | — | — | — | — |
Tepotinib monotherapy Variant #01 Partial | MET | — | 28d | — | — | — | — | — |
5 of 5 regimens shown